Raptor Pharma Wins Positive Opinion for Orphan Drug Exclusivity from EU Committee for PROCYSBI
July 22, 2013 at 07:20 AM EDT
Raptor Pharmaceutical Corp. (Nasdaq: RPTP ) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan Medicinal Products (COMP) recommending orphan drug exclusivity for PROCYSBI^® (mercaptamine) gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis. Final adoption of the opinions on drug approval and orphan exclusivity are